What question did this study set out to answer?

This study aims to evaluate clinical remission rates in severe eosinophilic asthma patients treated with benralizumab and identify predictors of remission.

April 26, 2026Open Access

Clinical Remission in Patients with Severe Eosinophilic Asthma – A Single-Arm Observational Study with Benralizumab

Key Points

This study aims to evaluate clinical remission rates in severe eosinophilic asthma patients treated with benralizumab and identify predictors of remission.
Data analyzed from prospective observational study (BEEPS, NCT03907137) in Switzerland.
Patients received benralizumab 30 mg at weeks 0, 4, and 8, then every 8 weeks until week 56.
Remission defined by specific criteria including ACQ-5 scores, exacerbation history, use of oral corticosteroids, and stable lung function.
At baseline, 0% of patients met all criteria for clinical remission.
After 56 weeks, 58.1% achieved remission with ACQ-5 < 1.5; 51.6% with ACQ-5 ≤ 0.75.
Asthma symptoms and annualized exacerbation rates consistently decreased across all subgroups throughout treatment.

Abstract

Purpose: To evaluate clinical remission rates and its individual components in patients with severe eosinophilic asthma treated with benralizumab, and to explore predictors of clinical remission using subgroup analyses by blood eosinophils, prior exacerbations, and previous biologic treatment. Patients and Methods: Data from a prospective, observational, non-interventional study (BEEPS, NCT03907137) of patients with severe eosinophilic asthma (SEA) in Switzerland were analysed post-hoc. Benralizumab 30 mg was administered at weeks 0 (baseline), 4, and 8, followed by an 8-weekly regimen until week 56. Clinical remission was defined as meeting all four of the following criteria: Asthma Control Questionnaire (ACQ-5) scores 400 cells/μL; (2) exacerbations in the last 12 months: < 4 and ≥ 4 exacerbations; (3) prior biologic treatment: naïve and experienced patients. Results: At baseline, no patients met all four criteria for clinical remission. After 56 weeks of benralizumab treatment, 58.1% of patients achieved all criteria when using ACQ-5 < 1.5, and 51.6% did so with ACQ-5 ≤ 0.75. Throughout the study, each individual remission criterion improved consistently over time. Across all subgroups, asthma symptoms and annualized exacerbation rates (AER) continuously decreased over the course of treatment. Conclusion: More than 50% of patients with SEA achieved clinical remission on treatment with benralizumab. Furthermore, benralizumab demonstrated consistent clinical efficacy across all patient subgroups, providing deeper insight into the characteristics and needs of these specific populations. Keywords: clinical remission, asthma symptom control, exacerbation reduction, OCS reduction, stratification by subgroups

Bookmark

View Full Paper